This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol 2018; 9(9): 273–93. doi: 10.1177/2040620718791933.DoshiBSArrudaVRGene therapy for hemophilia: what does the future hold?2018992739310.1177/2040620718791933613009930210756Open DOISearch in Google Scholar
Ohmori T. Advances in gene therapy for hemophilia: basis, current status, and future perspectives. Int J Hematol 2020; 111(1): 31–41. doi: 10.1007/s12185-018-2513-4.OhmoriTAdvances in gene therapy for hemophilia: basis, current status, and future perspectives20201111314110.1007/s12185-018-2513-430083852Open DOISearch in Google Scholar
Ohmori T, Mizukami H, Ozawa K, Sakata Y, Nishimura S. New approaches to gene and cell therapy for hemophilia. J Thromb Haemost 2015; 13(suppl 1): S133–42. doi: 10.1111/jth.12926.OhmoriTMizukamiHOzawaKSakataYNishimuraSNew approaches to gene and cell therapy for hemophilia201513suppl 1S1334210.1111/jth.1292626149014Open DOISearch in Google Scholar
Kumar SRP, Markusic DM, Biswas M, High KA, Herzog RW. Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 2016; 3: 16034. doi: 10.1038/mtm.2016.34.KumarSRPMarkusicDMBiswasMHighKAHerzogRWClinical development of gene therapy: results and lessons from recent successes201631603410.1038/mtm.2016.34487999227257611Open DOISearch in Google Scholar
Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med 2020; 382: 29–40. doi: 10.1056/NEJMoa1908490.PasiKJRangarajanSMitchellNMultiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A2020382294010.1056/NEJMoa190849031893514Open DOISearch in Google Scholar
Pipe S, Becka M, Detering E, Vanevski K, Lissitchkov T. First-in-human gene therapy study of AAVhu37 capsid vector technology in severe hemophilia A. Blood 2019; 134 (Supplement 1): 4630. doi: 10.1182/blood-2019-125764.PipeSBeckaMDeteringEVanevskiKLissitchkovTFirst-in-human gene therapy study of AAVhu37 capsid vector technology in severe hemophilia A2019134Supplement 1463010.1182/blood-2019-125764Open DOISearch in Google Scholar
Konkle BA, Stine K, Visweshwar N, et al. Initial results of the Alta Study, a phase 1/2, open label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy in adult subjects with severe hemophilia A. Blood 2019; 134 (Supplement 1): 2060. doi: 10.1182/blood-2019-122143.KonkleBAStineKVisweshwarNInitial results of the Alta Study, a phase 1/2, open label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy in adult subjects with severe hemophilia A2019134Supplement 1206010.1182/blood-2019-122143Open DOISearch in Google Scholar
High KA, George LA, Eyster ME, et al. A phase 1/2 trial of investigational Spk-8011 in hemophilia A demonstrates durable expression and prevention of bleeds. Blood 2018; 132 (Supplement 1): 487. doi: 10.1182/blood-2018-99-115495.HighKAGeorgeLAEysterMEA phase 1/2 trial of investigational Spk-8011 in hemophilia A demonstrates durable expression and prevention of bleeds2018132Supplement 148710.1182/blood-2018-99-115495Open DOISearch in Google Scholar
Nathwani AC, Reiss U, Tuddenham E, et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing “empty viral particles” on safety and efficacy of gene transfer. Blood 2018; 132 (Supplement 1): 491. doi: 10.1182/blood-2018-99-118334.NathwaniACReissUTuddenhamEAdeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing “empty viral particles” on safety and efficacy of gene transfer2018132Supplement 149110.1182/blood-2018-99-118334Open DOISearch in Google Scholar
Chowdary P, Shapiro S, Boyce S, et al. FLT180a: next generation AAV vector for haemophilia B – long term, follow-up and in-depth analysis of transgenic FIX using one-stage, chromogenic and global assays. ISTH Academy 2019; 263496; PB0309.ChowdaryPShapiroSBoyceSISTH Academy2019263496; PB0309.Search in Google Scholar
Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371(21): 1994–2004. doi: 10.1056/NEJMoa1407309.NathwaniACReissUMTuddenhamEGDLong-term safety and efficacy of factor IX gene therapy in hemophilia B2014371211994200410.1056/NEJMoa1407309427880225409372Open DOISearch in Google Scholar
Leebeek FWG, Meijer K, Coppens M, et al. Stable expression of FIX and maintained reductions in bleeding and factor IX consumption following AMT-060 gene therapy with up to 3.5 years of follow up in adults with severe or moderate-severe hemophilia B. ISTH Academy 2019; 274036; OC 01.4.LeebeekFWGMeijerKCoppensMISTH Academy2019274036; OC 01.4.Search in Google Scholar
Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv 2019; 3(21): 3241–47. doi: 10.1182/bloodadvances.2019000811.Von DrygalskiAGiermaszACastamanGEtranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B201932132414710.1182/bloodadvances.2019000811685510131698454Open DOISearch in Google Scholar
George LA, Sullivan SK, Rasko JEJ, et al. Efficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector fidanacogene elaparvovec and followed for at least 1 year. Blood 2019; 134 (Supplement 1): 3347. doi: 10.1182/blood-2019-124091.GeorgeLASullivanSKRaskoJEJEfficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector fidanacogene elaparvovec and followed for at least 1 year2019134Supplement 1334710.1182/blood-2019-124091Open DOISearch in Google Scholar
Stoffman J, Andersson NG, Branchford B, et al. Common themes and challenges in hemophilia care: a multinational perspective. Hematology 2019; 24: 39–48. doi: 10.1080/10245332.2018.1505225.StoffmanJAnderssonNGBranchfordBCommon themes and challenges in hemophilia care: a multinational perspective201924394810.1080/10245332.2018.150522530073913Open DOISearch in Google Scholar
Pollard D, Harrison C, Dodgson S, Holland M, Khair K. The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century. Haemophilia 2020; 26(4): 622–30. doi: 10.1111/hae.14002.PollardDHarrisonCDodgsonSHollandMKhairKThe UK haemophilia specialist nurse: Competencies fit for practice in the 21st century20202646223010.1111/hae.14002749622632311205Open DOISearch in Google Scholar
Miesbach W, Klamroth R. The patient experience of gene therapy for hemophilia: qualitative interviews with trial patients. Patient Pref Adherence 2020; 14: 767–70. doi: 10.2147/PPA.S239810.MiesbachWKlamrothRThe patient experience of gene therapy for hemophilia: qualitative interviews with trial patients2020147677010.2147/PPA.S239810718485832368018Open DOISearch in Google Scholar
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2008; 3: 77–101. doi: 10.1191/1478088706qp063oa.BraunVClarkeVUsing thematic analysis in psychology200837710110.1191/1478088706qp063oaOpen DOISearch in Google Scholar
Sundler AJ, Lindberg E, Nilsson C, Palmér L. Qualitative thematic analysis based on descriptive phenomenology. Nurs Open 2019; 6(3): 733–9. doi: 10.1002/nop2.275.SundlerAJLindbergENilssonCPalmérLQualitative thematic analysis based on descriptive phenomenology201963733910.1002/nop2.275665066131367394Open DOISearch in Google Scholar
UKRI Medical Research Council. Is my study research? Available from http://www.hra-decisiontools.org.uk/research/ (accessed 15 March 2021).UKRI Medical Research CouncilAvailable from http://www.hra-decisiontools.org.uk/research/ (accessed 15 March 2021).Search in Google Scholar
Van Balen EC, Wesselo ML, Baker BL, et al. Patient perspectives on novel treatments in haemophilia: a qualitative study. Patient 2020; 13(2): 201–10. doi: 10.1007/s40271-019-00395-6.Van BalenECWesseloMLBakerBLPatient perspectives on novel treatments in haemophilia: a qualitative study20201322011010.1007/s40271-019-00395-6707583831691206Open DOISearch in Google Scholar
Costea I, Isasi R, Knoppers BM, Lillicrap D. Haemophilia gene therapy: the patients' perspective. Haemophilia 2009; 15(5): 1159–61. doi: 10.1111/j.1365-2516.2009.02065.x.CosteaIIsasiRKnoppersBMLillicrapDHaemophilia gene therapy: the patients' perspective200915511596110.1111/j.1365-2516.2009.02065.x19601988Open DOISearch in Google Scholar
Woollard L, Gorman R, Rosenfelt DJ. Addressing patient education priorities in the era of gene therapy for haemophilia: Towards evidence–informed shared decision–making. Haemophilia 2020 Nov 27. doi: 10.1111/hae.14214. Online ahead of print.WoollardLGormanRRosenfeltDJAddressing patient education priorities in the era of gene therapy for haemophilia: Towards evidence–informed shared decision–making2020Nov2710.1111/hae.14214Online ahead of print.33245825Open DOISearch in Google Scholar
Peyvandi F, Lillicrap D, Mahlangu J, et al. Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Res Pract Thromb Haemost 2020; 4(4): 644–51. doi: 10.1002/rth2.12326.PeyvandiFLillicrapDMahlanguJHemophilia gene therapy knowledge and perceptions: Results of an international survey2020446445110.1002/rth2.12326729267332548564Open DOISearch in Google Scholar
Arcé C, Branchford B, Hart DP, et al. Optimizing language for effective communication of gene therapy concepts: A qualitative study. Presented at NHF Bleeding Disorders Conference 2019; PSO71. Available from https://www.hemophilia.org/research/research-projects/optimizing-language-for-effective-communication-of-gene-therapy-concepts-a-qualitative-study (accessed 15 March 2021).ArcéCBranchfordBHartDPPresented at NHF Bleeding Disorders Conference 2019PSO71Available from https://www.hemophilia.org/research/research-projects/optimizing-language-for-effective-communication-of-gene-therapy-concepts-a-qualitative-study (accessed 15 March 2021).Search in Google Scholar
Morris J. Patient advocacy helps patients weigh up gene therapy trial risk/benefits. J Haem Pract 2015; 2(1): 6–8. doi: 10.17225/jhp.00040.MorrisJPatient advocacy helps patients weigh up gene therapy trial risk/benefits2015216810.17225/jhp.00040Open DOISearch in Google Scholar
Forrester C, Bielby H, Johns S, Efford J, Holland M, Khair K, United Kingdom Haemophilia Nurse's Association. Potential for development of haemophilia link nurse role within UK hospitals. Haemophilia 2013; 19(4): 578–82. doi: 10.1111/hae.12144.ForresterCBielbyHJohnsSEffordJHollandMKhairKUnited Kingdom Haemophilia Nurse's AssociationPotential for development of haemophilia link nurse role within UK hospitals20131945788210.1111/hae.1214423560696Open DOISearch in Google Scholar
Khair K. Supporting adherence and improving quality of life in haemophilia care. Br J Nurs 2013; 22(12): 692. doi: 10.12968/bjon.2013.22.12.692.KhairKSupporting adherence and improving quality of life in haemophilia care2013221269210.12968/bjon.2013.22.12.69224151707Open DOISearch in Google Scholar
Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorb 2011; 1: 51–9. doi: 10.15256/joc.2011.1.2.KnobeKBerntorpEHaemophilia and joint disease: pathophysiology, evaluation, and management2011151910.15256/joc.2011.1.2555642129090136Open DOISearch in Google Scholar
Harrington C, Bedford M, Andritschke K, et al; EAHAD Nurses Committee. A European curriculum for nurses working in haemophilia. Haemophilia 2016; 22: 103–9. doi: 10.1111/hae.12785.HarringtonCBedfordMAndritschkeKEAHAD Nurses CommitteeA European curriculum for nurses working in haemophilia201622103910.1111/hae.1278526278710Open DOISearch in Google Scholar
Khair K. Minimizing joint damage: the role of nurses in promoting adherence to hemophilia treatment. Orthop Nurs 2010; 29(3): 193–200. doi: 10.1097/NOR.0b013e3181db53e8.KhairKMinimizing joint damage: the role of nurses in promoting adherence to hemophilia treatment201029319320010.1097/NOR.0b013e3181db53e820505489Open DOISearch in Google Scholar
Pierce GF, Coffin D, members of the WFH Gene Therapy Round Table Program Committee and Organizing Committee. The 1st WFH gene therapy round table: understanding the landscape and challenges of gene therapy for haemophilia around the world. Haemophilia 2019; 25(2): 189–194. doi: 10.1111/hae.13673.PierceGFCoffinDmembers of the WFH Gene Therapy Round Table Program Committee and Organizing CommitteeThe 1st WFH gene therapy round table: understanding the landscape and challenges of gene therapy for haemophilia around the world201925218919410.1111/hae.1367330604914Open DOISearch in Google Scholar
Hurst S, Warren C, Pasi KJ. Gene therapy in hemophilia: an assessment of hematologists’ knowledge gaps and attitudes. Blood; 2018; 132 (Supplement 1): 3485. doi: 10.1182/blood-2018-99-119116.HurstSWarrenCPasiKJGene therapy in hemophilia: an assessment of hematologists’ knowledge gaps and attitudes2018132Supplement 1348510.1182/blood-2018-99-119116Open DOISearch in Google Scholar
High KA, Roncarolo MG. Gene therapy. N Engl J Med 2019; 381: 455–64. doi: 10.1056/NEJMra1706910.HighKARoncaroloMGGene therapy20193814556410.1056/NEJMra170691031365802Open DOISearch in Google Scholar
Mulders G, De Wee EM, Vahedi Nikbakht-Van De Sande MCVM, Kruip MJHA, Elfrink EJ, Leebeek FWG. E-learning improves knowledge and practical skills in haemophilia patients on home treatment: a randomized controlled trial. Haemophilia 2012; 18(5): 693–8. doi: 10.1111/j.1365-2516.2012.02786.x.MuldersGDe WeeEMVahedi Nikbakht-Van De SandeMCVMKruipMJHAElfrinkEJLeebeekFWGE-learning improves knowledge and practical skills in haemophilia patients on home treatment: a randomized controlled trial2012185693810.1111/j.1365-2516.2012.02786.x22458978Open DOISearch in Google Scholar
Miesbach W, O’Mahony B, Key NS, Makris M. How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia 2019; 25(4): 545–57. doi: 10.1111/hae.13769.MiesbachWO’MahonyBKeyNSMakrisMHow to discuss gene therapy for haemophilia? A patient and physician perspective20192545455710.1111/hae.13769685220731115117Open DOISearch in Google Scholar